- Report
- March 2024
- 184 Pages
Global
From €3243EUR$3,374USD£2,742GBP
€3603EUR$3,749USD£3,047GBP
- Report
- November 2023
- 175 Pages
Global
From €4806EUR$5,000USD£4,064GBP
- Report
- May 2024
- 132 Pages
Global
From €6246EUR$6,499USD£5,282GBP
- Report
- May 2024
- 131 Pages
Global
From €6246EUR$6,499USD£5,282GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2883EUR$3,000USD£2,438GBP
- Report
- May 2024
- 132 Pages
Global
From €6246EUR$6,499USD£5,282GBP
- Report
- December 2023
- 140 Pages
Global
From €4277EUR$4,450USD£3,617GBP
- Report
- October 2023
- 145 Pages
Global
From €3028EUR$3,150USD£2,560GBP
- Report
- April 2023
- 180 Pages
Global
From €3124EUR$3,250USD£2,641GBP
- Report
- June 2023
- 338 Pages
Global
From €7208EUR$7,500USD£6,096GBP
- Report
- August 2020
- 114 Pages
Global
From €4085EUR$4,250USD£3,454GBP
- Report
- December 2018
- 48 Pages
Global
From €3359EUR$3,495USD£2,841GBP
- Report
- November 2020
- 199 Pages
Global
€4325EUR$4,500USD£3,657GBP
- Report
- October 2018
- 104 Pages
Global
From €2643EUR$2,750USD£2,235GBP
- Report
- January 2021
- 149 Pages
China, Global
From €3000EUR$3,344USD£2,626GBP
- Report
- June 2024
- 50 Pages
Global
From €2547EUR$2,650USD£2,154GBP
Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more